Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

Natacha Madelon; Nelli Heikkilä; Irène Sabater Royo; Paola Fontannaz; Gautier Breville; Kim Lauper; Rachel Goldstein; Alba Grifoni; Alessandro Sette; Claire-Anne Siegrist; Axel Finckh; Patrice H. Lalive; Arnaud M. Didierlaurent; Christiane S. Eberhardt

doi:10.1101/2021.12.20.21268128

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

Natacha Madelon, Nelli Heikkilä, Irène Sabater Royo, Paola Fontannaz, Gautier Breville, Kim Lauper, Rachel Goldstein, Alba Grifoni, Alessandro Sette, Claire-Anne Siegrist, Axel Finckh, Patrice H. Lalive, Arnaud M. Didierlaurent, Christiane S. Eberhardt

doi: https://doi.org/10.1101/2021.12.20.21268128

Natacha Madelon

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nelli Heikkilä

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Irène Sabater Royo

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

MSc

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paola Fontannaz

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gautier Breville

bDepartment of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim Lauper

cDepartment of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rachel Goldstein

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

MSc

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alba Grifoni

dCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alessandro Sette

dCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA

eDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Claire-Anne Siegrist

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

fDivision of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva; and Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Axel Finckh

cDepartment of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrice H. Lalive

bDepartment of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Arnaud M. Didierlaurent

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: Christiane.Eberhardt@unige.ch Arnaud.didierlaurent@unige.ch

Christiane S. Eberhardt

aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

gEmory Vaccine Center, Emory University School of Medicine, Atlanta, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: Christiane.Eberhardt@unige.ch Arnaud.didierlaurent@unige.ch

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

supplementray fig 1[supplements/268128_file04.pdf]

View the discussion thread.

PreviousNext

Posted December 21, 2021.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

medRxiv 2021.12.20.21268128; doi: https://doi.org/10.1101/2021.12.20.21268128

Share This Article:

Citation Tools

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

medRxiv 2021.12.20.21268128; doi: https://doi.org/10.1101/2021.12.20.21268128

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Tweet Widget
Facebook Like
Google Plus One

Subject Area

Allergy and Immunology

Subject Areas

All Articles

Addiction Medicine (381)
Allergy and Immunology (699)
Anesthesia (189)
Cardiovascular Medicine (2832)
Dentistry and Oral Medicine (324)
Dermatology (242)
Emergency Medicine (427)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1007)
Epidemiology (12531)
Forensic Medicine (10)
Gastroenterology (800)
Genetic and Genomic Medicine (4409)
Geriatric Medicine (400)
Health Economics (712)
Health Informatics (2838)
Health Policy (1045)
Health Systems and Quality Improvement (1045)
Hematology (373)
HIV/AIDS (893)
Infectious Diseases (except HIV/AIDS) (13952)
Intensive Care and Critical Care Medicine (827)
Medical Education (412)
Medical Ethics (114)
Nephrology (460)
Neurology (4167)
Nursing (220)
Nutrition (615)
Obstetrics and Gynecology (783)
Occupational and Environmental Health (721)
Oncology (2194)
Ophthalmology (623)
Orthopedics (254)
Otolaryngology (316)
Pain Medicine (265)
Palliative Medicine (81)
Pathology (485)
Pediatrics (1169)
Pharmacology and Therapeutics (486)
Primary Care Research (481)
Psychiatry and Clinical Psychology (3636)
Public and Global Health (6752)
Radiology and Imaging (1484)
Rehabilitation Medicine and Physical Therapy (863)
Respiratory Medicine (897)
Rheumatology (430)
Sexual and Reproductive Health (431)
Sports Medicine (365)
Surgery (471)
Toxicology (57)
Transplantation (200)
Urology (173)